Human recombinant activated protein C for severe sepsis (Q24242859)

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Drotrecogin alfa (activated) treatment of older patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Excess in the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Epidemiology of sepsis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Scope and impact of financial conflicts of interest in biomedical research: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

21 January 2018

Antibiotics in sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Financial relationships between institutional review board members and industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Critical advances in septicemia and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Lessons from the withdrawal of rofecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Drotrecogin Alfa (Activated) Administration: Too Many Subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

21 January 2018

The protein C pathway

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Protein C levels as a prognostic indicator of outcome in sepsis and related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Historical perspective of the word "sepsis".

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Multiple publication of reports of drug trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Recombinant human activated protein C in sepsis: assessing its clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

New and emerging therapies for sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Treatment of sepsis with activated protein C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Recombinant human activated protein C for severe sepsis in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Implications of pharmaceutical industry funding on clinical research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

The sirens are singing: The perils of trusting trials stopped early and subgroup analyses*

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Users' guide to detecting misleading claims in clinical research reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Using high quality clinical databases to complement the results of randomised controlled trials: the case of recombinant human activated protein C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Science review: role of coagulation protease cascades in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Organ dysfunction during sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Impact of covert duplicate publication on meta-analysis: a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Evidence-based medicine in the ICU: important advances and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Different patterns of duplicate publication: an analysis of articles used in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Risks and benefits of activated protein C treatment for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Human recombinant activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

Vioxx: an unequal partnership between safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

7 January 2021

An economic evaluation of activated protein C treatment for severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

7 January 2021

Recombinant human activated protein C in severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

7 January 2021

Applying patient selection criteria for drotrecogin alfa therapy in practice.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

7 January 2021

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

7 January 2021

Benefit of recombinant human activated protein C beyond 28-day mortality: there is more to life than death

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

7 January 2021

Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

7 January 2021

Substantiating the concerns about recombinant human activated protein C use in sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

7 January 2021

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

7 January 2021

A definite role for treatment with activated protein C in sepsis? Standard use is premature

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB3

7 January 2021

10.1002/14651858.CD004388.PUB3

Identifiers

DOI

0 references

Fatcat ID

release_g5d2jr4gy5hmfex5lxcwi7gxmy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/g5d2jr4gy5hmfex5lxcwi7gxmy

24 November 2022